This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Ascentawits Pharmaceuticals, Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jinwei Fan and a Safer Preparation Process for an Imidazole Compound.
Introduction
Jinwei Fan is an inventor based in Shenzhen, China, associated with Ascentawits Pharmaceuticals, Ltd. His patent work includes a preparation process for 1-N-methyl-2-nitro-5-hydroxymethylimidazole, a method designed to use a comparatively safer reagent.
Latest Patents
Fan is associated with 1 patent: “Preparation Process of 1-N-Methyl-2-Nitro-5-Hydroxymethyl Imidazole.” The invention describes reacting N,N′-carbonyldiimidazole with 1-N-methyl-2-aminoimidazole-5-carboxylic acid at 45–65°C, then cooling the mixture to 15–25°C until the reaction is complete. A reducing agent is subsequently used to obtain the target compound.
The process replaces isobutyl chloroformate, described in the patent as highly toxic, irritating, corrosive, and demanding in terms of environmental controls, with N,N′-carbonyldiimidazole (CDI). The patent highlights CDI’s solid form and comparatively manageable storage, transport, and handling characteristics. It also describes a straightforward reaction and workup, a higher reaction temperature intended to shorten processing time, and a route designed to limit side reactions and facilitate product purification.
Career Highlights
Fan’s documented patent contribution focuses on chemical-process development in pharmaceutical manufacturing. The disclosed method emphasizes reagent selection, reaction conditions, and workup steps intended to support efficient preparation of a high-purity product.
Collaborations
Fan is associated with Ascentawits Pharmaceuticals, Ltd. His listed coworkers include Yanjun Zhang and Qunhui Huang.
Conclusion
Jinwei Fan’s patent describes an alternative preparation route that replaces a more hazardous reagent with CDI and aims to simplify handling, shorten reaction time, and support product purification.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile